B

Bonus Biogroup Ltd
TASE:BONS

Watchlist Manager
Bonus Biogroup Ltd
TASE:BONS
Watchlist
Price: 9.9 ILS 1.02% Market Closed
Market Cap: 121.1m ILS
Have any thoughts about
Bonus Biogroup Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

-3.9
Current
-5.8
Median
4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-3.9
=
Enterprise Value
116.1m ILS
/
EBIT
-29.8m ILS
All Countries
Close
Market Cap EV/EBIT
IL
Bonus Biogroup Ltd
TASE:BONS
121.1m ILS -3.9
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 628.1
US
Abbvie Inc
NYSE:ABBV
315.2B USD 23.7
US
Amgen Inc
NASDAQ:AMGN
141.9B USD 30.4
US
Gilead Sciences Inc
NASDAQ:GILD
116.4B USD 10.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
104.5B USD 22.6
US
Epizyme Inc
F:EPE
94.1B EUR -499.6
AU
CSL Ltd
ASX:CSL
135.7B AUD 24.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
78.7B USD 17.1
US
Seagen Inc
F:SGT
39.3B EUR -52.9
NL
argenx SE
XBRU:ARGX
36B EUR -79.6
EBIT Growth EV/EBIT to Growth
IL
B
Bonus Biogroup Ltd
TASE:BONS
Average EV/EBIT: 21.5
Negative Multiple: -3.9
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 628.1 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.7
90%
0.3
US
Amgen Inc
NASDAQ:AMGN
30.4
90%
0.3
US
Gilead Sciences Inc
NASDAQ:GILD
10.3
32%
0.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.6
45%
0.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -499.6 N/A N/A
AU
CSL Ltd
ASX:CSL
24.8
54%
0.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.1
42%
0.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -52.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -79.6 N/A N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
N/A
2-Years Forward
EV/EBIT
N/A
3-Years Forward
EV/EBIT
N/A

See Also

Discover More